Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDC2501
- Development stage
- Preclinical
- Lead developer
- Prestige Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
IDC2501 is a biosimilar monoclonal antibody candidate developed by Prestige Biopharma (PBK) that targets the interleukin-4 receptor alpha (IL-4Rα) subunit. By binding to IL-4Rα, IDC2501 inhibits the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines in the Type 2 inflammatory pathway. This mechanism is intended to treat allergic and inflammatory conditions such as atopic dermatitis and asthma. As a biosimilar to dupilumab (Dupixent), IDC2501 is designed to provide a therapeutic alternative with the same mechanism of action and clinical efficacy as the reference product. The drug is currently in the preclinical stage of development.
- Other names
- dupilumab biosimilarIL-4R monoclonal antibody biosimilarIL4R monoclonal antibody biosimilarIL 4R monoclonal antibody biosimilar
02
Targets
IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on IDC2501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDC2501.